AnalystsInsight

David Risinger (Leerink Partners): Analyst Track Record and Price‑Target Accuracy

How often David Risinger’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 1,658 ratings, compared with the average Wall Street analyst.

3 min readHow we research

Key takeaways

  • David Risinger ranks #61 of 1,000 analysts in Exent’s scoring (5.0★).
  • 57.8% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 123 days; 70.1% of calls were up 12 months later.
  • Most‑covered stocks: LLY, EPA-SAN, REGN, BMY.

David Risinger’s track record at a glance

David Risinger of Leerink Partners ranks #61 of the 1,000 analysts Exent scores, with a 5.0★ rating and a focus on healthcare. Over a 7‑year lookback, 57.8% of David’s price targets were reached, 5.4 points above the 52.4% average across all analysts.

MetricDavid RisingerAll analysts
Price‑target hit rate57.8%52.4%
Median days to hit target123 days91 days
Calls up after 12 months70.1%64.0%
Median 12‑month return of calls+16.2%+13.4%
Hit rate, last 2 years54.6%—
Average worst drop after a call−16.4%—
Ratings in the sample1,658—
Stocks covered43—

How fast price targets were reached

Time to reach the targetDavid Risinger
Under 30 days17.8%
30–90 days18.5%
90–180 days29.9%
Over 180 days33.8%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks David Risinger covers most

StockRatings in the sample
LLY52
EPA-SAN38
REGN34
BMY30
AMGN27
ANAB24
ORKA21
ABBV21

In the past year David’s ratings were 80% Buy, 20% Hold and 0% Sell.

Recent ratings (shown with a 30-day delay)

DateStockActionRatingPrice target
Sep 16, 2026LLYReiterated: BuyBuy$0.00
Aug 18, 2026SCTXInitiated Coverage: BuyBuy$37.00
Aug 17, 2026REGNReiterated: HoldHold$824.00
Aug 11, 2026TENXReiterated: BuyBuy$4.00
Aug 7, 2026HALOUpgraded: BuyBuy$110.00
Jul 17, 2026LLYReiterated: BuyBuy$0.00
Jul 17, 2026JNJReiterated: BuyBuy$276.00
Jun 25, 2026LLYMaintained: BuyBuy$1232.00
Jun 25, 2026LLYReiterated: BuyBuy$1232.00
Jun 2, 2026ORKAReiterated: BuyBuy$0.00
Jun 2, 2026ORKAReiteratedBuy—
Jun 2, 2026LLYReiterated: BuyBuy$0.00
  • Sep 16, 2026
    Stock
    LLY
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 18, 2026
    Stock
    SCTX
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $37.00
  • Aug 17, 2026
    Stock
    REGN
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $824.00
  • Aug 11, 2026
    Stock
    TENX
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $4.00
  • Aug 7, 2026
    Stock
    HALO
    Action
    Upgraded: Buy
    Rating
    Buy
    Price target
    $110.00
  • Jul 17, 2026
    Stock
    LLY
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Jul 17, 2026
    Stock
    JNJ
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $276.00
  • Jun 25, 2026
    Stock
    LLY
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $1232.00
  • Jun 25, 2026
    Stock
    LLY
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $1232.00
  • Jun 2, 2026
    Stock
    ORKA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Jun 2, 2026
    Stock
    ORKA
    Action
    Reiterated
    Rating
    Buy
    Price target
    —
  • Jun 2, 2026
    Stock
    LLY
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00

Live ratings from David Risinger and the other top‑ranked analysts, and the stocks where they agree, are in Exent Stocks Radar.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 16, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Stocks Radar shows David Risinger’s live ratings and those of the other top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring David Risinger ranks #61 of 1,000 with a 5.0★ rating. 57.8% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 70.1% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

David Risinger’s success rate is 65.0% by the ranking source and 57.8% by Exent’s price-target hit-rate backtest, with a median of 123 days to reach a target.

David Risinger (Leerink Partners) covers 43 stocks, mostly in healthcare. The most frequently rated are LLY, EPA-SAN, REGN, BMY, AMGN.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.